Procalcitonin as a biomarker for ventilator associated pneumonia in COVID-19 patients: Is it an useful stewardship tool?

Diagn Microbiol Infect Dis. 2021 Feb 12;101(2):115344. doi: 10.1016/j.diagmicrobio.2021.115344. Online ahead of print.

ABSTRACT

Ventilator associated pneumonia(VAP) is a severe complication that can lead to high mortality when not early identified or when therapy is delayed. The aim of this study was to evaluate procalcitonin(PCT) as a biomarker for VAP development. In total, 73 hospitalized patients with COVID-19 were analyzed. PCT levels greater than 0.975ng/mL were more related to VAP. No association was found for C-reactive protein (CRP). The results show that procalcitonin may be a pertinent biomarker for VAP diagnosis and can be a helpful tool for antibiotic withdrawal.

PMID:34243136 | PMC:PMC7879055 | DOI:10.1016/j.diagmicrobio.2021.115344